Exact Mass: 508.211
Exact Mass Matches: 508.211
Found 500 metabolites which its exact mass value is equals to given mass value 508.211
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Difluprednate
Difluprednate is only found in individuals that have used or taken this drug. It is a topical corticosteroid indicated for the treatment of inflammation and pain associated with ocular surgery. It was approved by the US Food and Drug Administration (FDA) on June 24, 2008. Corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins (lipocortins). It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. D - Dermatologicals > D07 - Corticosteroids, dermatological preparations > D07A - Corticosteroids, plain > D07AC - Corticosteroids, potent (group iii) D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D005938 - Glucocorticoids C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C308 - Immunotherapeutic Agent > C574 - Immunosuppressant > C211 - Therapeutic Corticosteroid Same as: D01266 Difluprednate is a topical corticosteroid, which is thought to act by the induction of phospholipase A2 inhibitory proteins (lipocortins). Difluprednate is used for the symptomatic treatment of inflammation and pain associated with ocular surgery.
(7'R,8'R)-4,7'-Epoxy-3'-methoxy-4',5,9,9'-lignanetetrol 9'-glucoside
(7R,8R)-4,7-Epoxy-3-methoxy-4,5,9,9-lignanetetrol 9-glucoside is found in alcoholic beverages. (7R,8R)-4,7-Epoxy-3-methoxy-4,5,9,9-lignanetetrol 9-glucoside is isolated from Riesling wine. Isolated from Riesling wine. (7R,8R)-4,7-Epoxy-3-methoxy-4,5,9,9-lignanetetrol 9-glucoside is found in alcoholic beverages.
6-O-Oleuropeoylsucrose
6-O-Oleuropeoylsucrose is a constituent of the root bark of the olive (Olea europaea). Constituent of the root bark of the olive (Olea europaea)
Tert-butyl N-[(2S,3R)-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl-propan-2-yloxyamino]-1-phenylbutan-2-yl]carbamate
Difluprednatum
Belnacasan
Cyclodeca[b]furan-6-carboxylicacid,5-(acetyloxy)-4-[3-(acetyloxy)-2-hydroxy-2-methyl-1-oxobutoxy]-2,3,3a,4,5,8,9,11a-octahydro-10-methyl-3-methylene-2-oxo-,methyl ester (9CI)
Mortonin C
Mortonin D
[7-(hydroxymethyl)-4-methyl-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-5-yl] (E)-3-(4-hydroxyphenyl)prop-2-enoate
(7R,8S)-9,3,9-trihydroxyl-3-methoxyl-7,8-dihydrobenzofuran-1-propylneolignan-4-O-beta-D-glucopyranoside
(7S,8S)-3-methoxy-3,7-epoxy-8,4-oxyneoligna-4,9-diol 9-O-beta-D-glucopyranoside|junipercomnoside C
(alphaS)-alpha-[(methoxycarbonyl)amino]-4,6-dimethyl-9-oxo-3-beta-D-ribofuranosyl-4,9-dihydro-3H-imidazo[1,2-alpha]purine-7-butanoic acid methyl ester|(alphaS)-alpha-[(methoxycarbonyl)amino]-4,6-dimethyl-9-oxo-3-beta-D-ribofuranosyl-4,9-dihydro-3H-imidazo[1,2-a]purine-7-butanoic acid methyl ester|(S)-4--4,6-dimethyl-9-oxo-3-(beta-D-ribofuranosyl)-4,9-dihydro-3H-imidazo<1,2-a>purin-7-yl>butanoic acid methyl ester|wybutosine|yW
Bruceine J
bruceine J is a natural product found in Brucea javanica with data available.
(7R,8R)-3-methoxy-3,7-epoxy-8,4-oxyneoligna-4,9-diol 9-O-beta-D-glucopyranoside|junipercomnoside D
8-hydroxy-(+)-isolariciresinol-9-O-beta-D-xylopyranoside
5,4-dihydroxy-3-(alpha-L-rhamnosyl-(1->3)-beta-D-xylopyranosyloxy)bibenzyl|5,4-Dihydroxy-3-??-L-rhamnosyl-(1鈥樏傗垎3)-??-D-xylopyranosyloxybibenzyl
(2R)-2-[(S)-3-hydroxy-3-methylglutaryloxy]putrescine dicinnamamide|pholiotic acid
Asp Phe Val Glu
Val Glu Phe Asp
(E)-1-(glutathion-S-yl)-N-hydroxy-omega-(methylsulfanyl)nonan-1-imine
Indacaterol Maleate
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist Indacaterol maleate (QAB149) is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol maleate inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol maleate can also be used in cardiovascular disease research[1][2].
MLS001148580-01!6ALPHA,9ALPHA-DIFLUOROPREDNISOLONE 21-ACETATE 17-BUTYRATE
(5S)-1,7-bis(3,4-dihydroxyphenyl)-5-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptan-3-one
Ala Gln Gln Tyr
Ala Gln Tyr Gln
Ala Tyr Gln Gln
Cys Cys Lys Arg
Cys Cys Arg Lys
Cys His His Ile
Cys His His Leu
Cys His Ile His
Cys His Leu His
Cys Ile His His
Cys Lys Cys Arg
Cys Lys Met Gln
Cys Lys Gln Met
Cys Lys Arg Cys
Cys Leu His His
Cys Met Lys Gln
Cys Met Gln Lys
Cys Gln Lys Met
Cys Gln Met Lys
Cys Arg Cys Lys
Cys Arg Lys Cys
Asp Asp Phe Ile
Asp Asp Phe Leu
Asp Asp Ile Phe
Asp Asp Leu Phe
Asp Glu Phe Val
Asp Glu Val Phe
Asp Phe Asp Ile
Asp Phe Asp Leu
Asp Phe Glu Val
Asp Phe Ile Asp
Asp Phe Leu Asp
Asp Phe Met Pro
Asp Phe Asn Asn
Asp Phe Pro Met
Asp His His Thr
Asp His Thr His
Asp Ile Asp Phe
Asp Ile Phe Asp
Asp Ile Met Met
Asp Leu Asp Phe
Asp Leu Phe Asp
Asp Leu Met Met
Asp Met Phe Pro
Asp Met Ile Met
Asp Met Leu Met
Asp Met Met Ile
Asp Met Met Leu
Asp Met Pro Phe
Asp Asn Phe Asn
Asp Asn Asn Phe
Asp Pro Phe Met
Asp Pro Met Phe
Asp Thr His His
Asp Val Glu Phe
Asp Val Phe Glu
Glu Asp Phe Val
Glu Asp Val Phe
Glu Phe Asp Val
Glu Phe Val Asp
Glu His His Ser
Glu His Ser His
Glu Met Met Val
Glu Met Val Met
Glu Pro Thr Tyr
Glu Pro Tyr Thr
Glu Ser His His
Glu Thr Pro Tyr
Glu Thr Tyr Pro
Glu Val Asp Phe
Glu Val Phe Asp
Glu Val Met Met
Glu Tyr Pro Thr
Glu Tyr Thr Pro
Phe Asp Asp Ile
Phe Asp Asp Leu
Phe Asp Glu Val
Phe Asp Ile Asp
Phe Asp Leu Asp
Phe Asp Met Pro
Phe Asp Asn Asn
Phe Asp Pro Met
Phe Asp Val Glu
Phe Glu Asp Val
Phe Glu Val Asp
Phe Ile Asp Asp
Phe Leu Asp Asp
Phe Met Asp Pro
Phe Met Pro Asp
Phe Asn Asp Asn
Phe Asn Asn Asp
Phe Asn Gln Thr
Phe Asn Thr Gln
Phe Pro Asp Met
Phe Pro Met Asp
Phe Gln Asn Thr
Phe Gln Gln Ser
Phe Gln Ser Gln
Phe Gln Thr Asn
Phe Ser Gln Gln
Phe Thr Asn Gln
Phe Thr Gln Asn
Phe Val Asp Glu
Phe Val Glu Asp
His Cys His Ile
His Cys His Leu
His Cys Ile His
His Cys Leu His
His Asp His Thr
His Asp Thr His
His Glu His Ser
His Glu Ser His
His His Cys Ile
His His Cys Leu
His His Asp Thr
His His Glu Ser
His His Ile Cys
His His Leu Cys
His His Ser Glu
His His Thr Asp
His Ile Cys His
His Ile His Cys
His Leu Cys His
His Leu His Cys
His Ser Glu His
His Ser His Glu
His Thr Asp His
His Thr His Asp
Ile Cys His His
Ile Asp Asp Phe
Ile Asp Phe Asp
Ile Asp Met Met
Ile Phe Asp Asp
Ile His Cys His
Ile His His Cys
Ile Met Asp Met
Ile Met Met Asp
Lys Cys Cys Arg
Lys Cys Met Gln
Lys Cys Gln Met
Lys Cys Arg Cys
Lys Met Cys Gln
Lys Met Gln Cys
Lys Gln Cys Met
Lys Gln Met Cys
Lys Arg Cys Cys
Leu Cys His His
Leu Asp Asp Phe
Leu Asp Phe Asp
Leu Asp Met Met
Leu Phe Asp Asp
Leu His Cys His
Leu His His Cys
Leu Met Asp Met
Leu Met Met Asp
Met Cys Lys Gln
Met Cys Gln Lys
Met Asp Phe Pro
Met Asp Ile Met
Met Asp Leu Met
Met Asp Met Ile
Met Asp Met Leu
Met Asp Pro Phe
Met Glu Met Val
Met Glu Val Met
Met Phe Asp Pro
Met Phe Pro Asp
Met Ile Asp Met
Met Ile Met Asp
Met Lys Cys Gln
Met Lys Gln Cys
Met Leu Asp Met
Met Leu Met Asp
Met Met Asp Ile
Met Met Asp Leu
Met Met Glu Val
Met Met Ile Asp
Met Met Leu Asp
Met Met Val Glu
Met Pro Asp Phe
Met Pro Phe Asp
Met Gln Cys Lys
Met Gln Lys Cys
Met Val Glu Met
Met Val Met Glu
Asn Asp Phe Asn
Asn Asp Asn Phe
Asn Phe Asp Asn
Asn Phe Asn Asp
Asn Phe Gln Thr
Asn Phe Thr Gln
Asn Asn Asp Phe
Asn Asn Phe Asp
Asn Asn Val Tyr
Asn Asn Tyr Val
Asn Gln Phe Thr
Asn Gln Thr Phe
Asn Thr Phe Gln
Asn Thr Gln Phe
Asn Val Asn Tyr
Asn Val Tyr Asn
Asn Tyr Asn Val
Asn Tyr Val Asn
Pro Asp Phe Met
Pro Asp Met Phe
Pro Glu Thr Tyr
Pro Glu Tyr Thr
Pro Phe Asp Met
Pro Phe Met Asp
Pro Met Asp Phe
Pro Met Phe Asp
Pro Thr Glu Tyr
Pro Thr Tyr Glu
Pro Tyr Glu Thr
Pro Tyr Thr Glu
Gln Ala Gln Tyr
Gln Ala Tyr Gln
Gln Cys Lys Met
Gln Cys Met Lys
Gln Phe Asn Thr
Gln Phe Gln Ser
Gln Phe Ser Gln
Gln Phe Thr Asn
Gln Lys Cys Met
Gln Lys Met Cys
Gln Met Cys Lys
Gln Met Lys Cys
Gln Asn Phe Thr
Gln Asn Thr Phe
Gln Gln Ala Tyr
Gln Gln Phe Ser
Gln Gln Ser Phe
Gln Gln Tyr Ala
Gln Ser Phe Gln
Gln Ser Gln Phe
Gln Thr Phe Asn
Gln Thr Asn Phe
Gln Tyr Ala Gln
Gln Tyr Gln Ala
Arg Cys Cys Lys
Arg Cys Lys Cys
Arg Lys Cys Cys
Ser Glu His His
Ser Phe Gln Gln
Ser His Glu His
Ser His His Glu
Ser Gln Phe Gln
Ser Gln Gln Phe
Thr Asp His His
Thr Glu Pro Tyr
Thr Glu Tyr Pro
Thr Phe Asn Gln
Thr Phe Gln Asn
Thr His Asp His
Thr His His Asp
Thr Asn Phe Gln
Thr Asn Gln Phe
Thr Pro Glu Tyr
Thr Pro Tyr Glu
Thr Gln Phe Asn
Thr Gln Asn Phe
Thr Tyr Glu Pro
Thr Tyr Pro Glu
Val Asp Glu Phe
Val Asp Phe Glu
Val Glu Asp Phe
Val Glu Met Met
Val Phe Asp Glu
Val Phe Glu Asp
Val Met Glu Met
Val Met Met Glu
Val Asn Asn Tyr
Val Asn Tyr Asn
Val Tyr Asn Asn
Tyr Ala Gln Gln
Tyr Glu Pro Thr
Tyr Glu Thr Pro
Tyr Asn Asn Val
Tyr Asn Val Asn
Tyr Pro Glu Thr
Tyr Pro Thr Glu
Tyr Gln Ala Gln
Tyr Gln Gln Ala
Tyr Thr Glu Pro
Tyr Thr Pro Glu
Tyr Val Asn Asn
(7'R,8'R)-4,7'-Epoxy-3'-methoxy-4',5,9,9'-lignanetetrol 9'-glucoside
6alpha,9-difluoro-11beta-hydroxy-16alpha,17-[isopropylidenebis(oxy)]pregna-1,4-diene-3,20-dione 21-propionate
1,1,3,3,3,3-hexamethylindotricarbocyanine perchlorate
VX-765
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C38461 - Caspase Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Lonaprisan
C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C1891 - Progesterone Antagonist
L-Prolinamide, N-(4-amino-3-chlorobenzoyl)-3-methylvalyl-N-(2-ethoxytetrahydro-5-oxo-3-furanyl)-
2-[[6-(4-morpholinyl)-4-oxo-3-(2-phenylethyl)-2-quinazolinyl]thio]-N-(2-oxolanylmethyl)acetamide
Difluprednate
D - Dermatologicals > D07 - Corticosteroids, dermatological preparations > D07A - Corticosteroids, plain > D07AC - Corticosteroids, potent (group iii) D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D005938 - Glucocorticoids C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C308 - Immunotherapeutic Agent > C574 - Immunosuppressant > C211 - Therapeutic Corticosteroid Same as: D01266 Difluprednate is a topical corticosteroid, which is thought to act by the induction of phospholipase A2 inhibitory proteins (lipocortins). Difluprednate is used for the symptomatic treatment of inflammation and pain associated with ocular surgery.
(1R,2R,5S,8S,9S,10R,11R,12S)-5-hydroxy-11-methyl-6-methylidene-16-oxo-12-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadec-13-ene-9-carboxylic acid
(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-[(E)-N-hydroxy-C-(8-methylsulfanyloctyl)carbonimidoyl]sulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
N-[4-[[2-methoxy-5-[4-oxo-3-(pyridin-4-ylmethyl)-1,2-dihydroquinazolin-2-yl]phenyl]methoxy]phenyl]acetamide
N-[5-(diethylsulfamoyl)-2-(4-morpholinyl)phenyl]-2,3-dihydro-1H-cyclopenta[b]quinoline-9-carboxamide
1-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-[4-(trifluoromethyl)phenyl]urea
1-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-[4-(trifluoromethyl)phenyl]urea
N-[(1S,3S,4aS,9aR)-3-[2-(cyclohexylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
1-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-[4-(trifluoromethyl)phenyl]urea
1-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-[4-(trifluoromethyl)phenyl]urea
N-[(1R,3R,4aS,9aR)-3-[2-(cyclohexylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1R,3R,4aR,9aS)-3-[2-(cyclohexylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1S,3S,4aR,9aS)-3-[2-(cyclohexylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1R,3S,4aS,9aR)-3-[2-(cyclohexylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
1-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-[4-(trifluoromethyl)phenyl]urea
1-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-[4-(trifluoromethyl)phenyl]urea
1-[(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-[4-(trifluoromethyl)phenyl]urea
1-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-[4-(trifluoromethyl)phenyl]urea
1-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-[4-(trifluoromethyl)phenyl]urea
1-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-[4-(trifluoromethyl)phenyl]urea
1-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-[4-(trifluoromethyl)phenyl]urea
1-[(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-[4-(trifluoromethyl)phenyl]urea
N-[(1S,3R,4aS,9aR)-3-[2-(cyclohexylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1S,3R,4aR,9aS)-3-[2-(cyclohexylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[4-[[2-(diethylamino)ethylamino]-oxomethyl]phenyl]-3-[(4-methylphenyl)sulfamoyl]benzamide
(7R,8R)-4,7-Epoxy-3-methoxy-4,5,9,9-lignanetetrol 9-glucoside
BI-1622
BI-1622 is an orally active, potent and highly selective HER2 (ERBB2) inhibitor, with an IC50 of 7 nM. BI-1622 shows greater than 25-fold selectivity over EGFR. BI-1622 shows high antitumor efficacy in vivo in xenograft mouse tumor models with engineered H2170 and PC9 cells and had a favorable agent metabolism and pharmacokinetics profile[1].
methyl 5-(acetyloxy)-4-{[3-(acetyloxy)-2-hydroxy-2-methylbutanoyl]oxy}-10-methyl-3-methylidene-2-oxo-3ah,4h,5h,8h,9h,11ah-cyclodeca[b]furan-6-carboxylate
(2r,3r,4s,5s,6s)-2-{[(2r,3r)-3-(4-hydroxy-3-methoxyphenyl)-6-(3-hydroxypropyl)-2,3-dihydro-1,4-benzodioxin-2-yl]methoxy}-6-methoxyoxane-3,4,5-triol
(2r,3r,4r,5r,6s)-2-{[(2r,3s,4s,5r)-3,5-dihydroxy-2-{3-hydroxy-5-[2-(4-hydroxyphenyl)ethyl]phenoxy}oxan-4-yl]oxy}-6-methyloxane-3,4,5-triol
(1s,2s,4s,5s,6r,9s,12r,17r)-12-isopropyl-1,6-dimethyl-5-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3,8,13-trioxapentacyclo[7.7.1.0²,⁴.0⁶,¹⁷.0¹¹,¹⁶]heptadeca-10,15-diene-7,14-dione
(9r)-3,4,5,19-tetramethoxy-9,10-dimethyl-8-phenoxy-15,17-dioxatetracyclo[10.7.0.0²,⁷.0¹⁴,¹⁸]nonadeca-1(12),2(7),3,5,13,18-hexaen-9-ol
(2r,3r,4s,5s,6r)-2-{[(2r,3r)-7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-5-(3-hydroxypropyl)-2,3-dihydro-1-benzofuran-3-yl]methoxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(2s,3r,4r,5r,6s)-2-{[(2s,3r,4s,5r)-3,5-dihydroxy-2-{3-hydroxy-5-[2-(4-hydroxyphenyl)ethyl]phenoxy}oxan-4-yl]oxy}-6-methyloxane-3,4,5-triol
5-hydroxy-11-methyl-6-methylidene-16-oxo-12-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-15-oxapentacyclo[9.3.2.1⁵,⁸.0¹,¹⁰.0²,⁸]heptadec-13-ene-9-carboxylic acid
(1s,2s,5s)-2-[(1r)-1-carboxy-2-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2e)-3-phenylprop-2-enoyl]oxy}methyl)oxan-2-yl]oxy}ethyl]-5-methylcyclopentane-1-carboxylic acid
(2r,3s)-2,3-dihydro-7-hydroxy-2-(4'-hydroxy-3'-methoxyphenyl)-3-hydroxymethyl-5-benzo-furanpropanol 4'-o-β-d-glucopyranoside
{"Ingredient_id": "HBIN006465","Ingredient_name": "(2r,3s)-2,3-dihydro-7-hydroxy-2-(4'-hydroxy-3'-methoxyphenyl)-3-hydroxymethyl-5-benzo-furanpropanol 4'-o-\u03b2-d-glucopyranoside","Alias": "NA","Ingredient_formula": "C25H32O11","Ingredient_Smile": "COC1=C(C=CC(=C1)C2C(C3=CC(=CC(=C3O2)O)CCCO)CO)OC4C(C(C(C(O4)CO)O)O)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "5633","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
(2s,3r)-2,3-dihydro-7-hydroxy-2-(4'-hydroxy-3'-methoxyphenyl)-3-hydroxymethyl-5-benzo-furanpropanol 4'-o-β-d-glucopyranoside
{"Ingredient_id": "HBIN006622","Ingredient_name": "(2s,3r)-2,3-dihydro-7-hydroxy-2-(4'-hydroxy-3'-methoxyphenyl)-3-hydroxymethyl-5-benzo-furanpropanol 4'-o-\u03b2-d-glucopyranoside","Alias": "NA","Ingredient_formula": "C25H32O11","Ingredient_Smile": "COC1=C(C=CC(=C1)C2C(C3=CC(=CC(=C3O2)O)CCCO)CO)OC4C(C(C(C(O4)CO)O)O)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "5634","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
5,4'-dihydroxy-3-α-l-rhamnosyl-(1''→3')-β-d-xylopyranosyloxybibenzyl
{"Ingredient_id": "HBIN011042","Ingredient_name": "5,4'-dihydroxy-3-\u03b1-l-rhamnosyl-(1''\u21923')-\u03b2-d-xylopyranosyloxybibenzyl","Alias": "NA","Ingredient_formula": "C25H32O11","Ingredient_Smile": "CC1C(C(C(C(O1)OC2C(COC(C2O)OC3=CC(=CC(=C3)O)CCC4=CC=C(C=C4)O)O)O)O)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "6107","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
ajugalide a
{"Ingredient_id": "HBIN014969","Ingredient_name": "ajugalide a","Alias": "NA","Ingredient_formula": "C26H36O10","Ingredient_Smile": "CC1CC(C2(C(C1(C)CC(C3=CC(=O)OC3)OC(=O)C)C(CCC24CO4)O)COC(=O)C)OC(=O)C","Ingredient_weight": "508.6 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "795","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "12136677","DrugBank_id": "NA"}
alboside i
{"Ingredient_id": "HBIN015087","Ingredient_name": "alboside i","Alias": "NA","Ingredient_formula": "C25H32O11","Ingredient_Smile": "CC1C(CC2C1C(OC=C2)OC3C(C(C(C(O3)CO)O)O)OC(=O)C=CC4=CC(=C(C=C4)O)OC)O","Ingredient_weight": "508.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "867","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "100982915","DrugBank_id": "NA"}